FDA-Approved Cannabis-Based Medications: Epidiolex, Marinol, and More
Four medications derived from cannabis or its active compounds have cleared the FDA's full approval process — a fact that surprises people on both sides of the marijuana debate. These drugs exist in a different legal universe from state-licensed dispensary cannabis, regulated under federal pharmaceutical law rather than patchwork state programs, and they carry the clinical evidence trail that most plant-based cannabis products still lack.
Definition and Scope
The FDA has approved cannabis-derived and cannabis-related drugs through its standard New Drug Application process, meaning each product survived randomized controlled trials, peer review, and agency scrutiny of manufacturing quality. That process is meaningfully different from the state-level frameworks covered in the regulatory context for medical marijuana.
The four approved drugs fall into two structural categories:
Cannabis-derived (plant-sourced cannabinoids)
- Epidiolex (cannabidiol, CBD) — approved by the FDA in June 2018 for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex, per FDA drug approval records
Synthetic cannabinoid-based drugs
- Marinol (dronabinol, synthetic THC) — Schedule III, approved for chemotherapy-induced nausea/vomiting and AIDS-related anorexia
- Syndros (dronabinol oral solution) — Schedule II, same indications as Marinol but in liquid form, placed in a more restrictive schedule because of its faster absorption profile
- Cesamet (nabilone, a synthetic cannabinoid analog) — Schedule II, approved for chemotherapy-induced nausea/vomiting in patients who haven't responded to conventional antiemetics
Epidiolex is the only drug in this group derived from actual cannabis plant material. The others use synthetic molecules that mimic THC's structure or receptor activity.
How It Works
Each drug operates on the endocannabinoid system but through meaningfully different mechanisms.
Epidiolex's exact anticonvulsant mechanism is not fully characterized, which is itself an honest and unusual admission for an FDA drug label. CBD appears to modulate sodium and calcium ion channels, reduce neuronal excitability, and interact with GPR55 receptors, according to the Epidiolex prescribing information. It does not produce the psychoactive effects associated with THC.
Dronabinol (Marinol and Syndros) works as a partial agonist at CB1 and CB2 cannabinoid receptors — the same receptors that plant-derived THC activates. At therapeutic doses it suppresses the vomiting reflex through CB1 receptors in the medulla and stimulates appetite through hypothalamic pathways. The psychoactive effect is real and dose-dependent, which is why patient counseling on these drugs includes impairment warnings.
Nabilone (Cesamet) is structurally distinct from THC but binds the same CB1 and CB2 receptors with slightly higher receptor affinity. Its half-life of roughly 2 hours — compared to dronabinol's more variable profile — gives it a somewhat more predictable dosing curve, though individual responses vary considerably.
Common Scenarios
These drugs appear in specific, bounded clinical situations rather than functioning as broad alternatives to plant-based medical marijuana.
-
Pediatric refractory epilepsy — Epidiolex is the only FDA-approved option for Dravet syndrome and Lennox-Gastaut syndrome. A pivotal trial published in the New England Journal of Medicine (Devinsky et al., 2017) showed a median 38.9% reduction in convulsive seizure frequency versus 13.3% with placebo in Dravet patients.
-
Oncology-related nausea — Marinol, Syndros, and Cesamet are prescribed when standard antiemetics (typically 5-HT3 antagonists or corticosteroids) fail or produce intolerable side effects. They are not first-line choices in most oncology protocols.
-
HIV/AIDS-related anorexia — Marinol has an approved indication for appetite stimulation in AIDS patients experiencing weight loss, though clinical use has become less common as HIV treatment protocols have evolved.
-
Palliative care settings — Dronabinol is sometimes used off-label for nausea in non-oncology palliative patients, a use pattern documented in hospice and palliative medicine literature but outside the formal FDA indication.
For patients navigating cannabis-based options more broadly, the medical marijuana for epilepsy and seizures page covers how Epidiolex fits alongside state-program cannabis access.
Decision Boundaries
The line between these FDA-approved drugs and state-licensed medical marijuana is sharper than it might appear, and the distinctions matter in practical ways.
Schedule status matters for access. Epidiolex's rescheduling to Schedule V (the least restrictive DEA schedule for controlled substances) after approval means it can be prescribed through a standard DEA registration — no special state medical marijuana card required. Marinol and Cesamet sit at Schedule II and III respectively, requiring standard controlled substance prescribing authority.
Insurance coverage differs. FDA-approved drugs can be covered by Medicare, Medicaid, and commercial insurance through normal pharmacy benefit pathways, unlike dispensary cannabis. This single structural fact puts Epidiolex financially within reach for families who would otherwise face out-of-pocket costs averaging hundreds of dollars monthly for CBD products. Medical marijuana insurance coverage addresses the reimbursement landscape in more detail.
Evidence standards are categorically different. FDA approval requires phase III randomized controlled trial data. The broader medical marijuana landscape covered on this site's overview operates largely on observational data, patient registries, and pre-clinical research.
Off-label use is not prohibited but is uncharted. Physicians may prescribe Marinol for indications beyond the approved label, but that shifts the liability calculus and removes the insurance coverage anchor that makes the approved indications economically viable.
The practical tension is real: a patient with treatment-resistant nausea might qualify for a state medical marijuana program, have access to dozens of cannabis products at a dispensary, and still find that only dronabinol is reimbursable through their pharmacy plan — even if plant-derived THC would produce a comparable effect at lower cost.